Prescriber Scope of Practice for Weight Loss/GLP-1 in Illinois

You’re a psychiatrist who’s spent years treating ADHD and depression. Lately, you’ve noticed something: half your patients are asking about GLP-1 medications for weight loss, or they’re gaining significant weight from the antipsychotics you’ve prescribed. You wonder—can I help them with this? Can you prescribe semaglutide or phentermine via telehealth, or is this outside your scope?

The short answer: Yes, psychiatrists can legally prescribe weight-loss medications—you hold an unrestricted medical license. But the reality is more complex. Between evolving DEA rules for controlled substances, state-specific telehealth restrictions, and scope-of-practice questions (especially for PMHNPs), navigating weight-loss prescribing feels like walking through a regulatory minefield.

Let’s cut through the confusion. This guide breaks down what psychiatric providers need to know about prescribing weight-loss medications via telehealth in 2025-2026, covering federal DEA rules, state laws in California, Texas, Florida, New York, Pennsylvania, and Illinois, and the practical economics of building this into your practice.

The Federal Telehealth Landscape: DEA Rules Through 2026

The Ryan Haight Act and COVID Flexibilities

Pre-pandemic, federal law (the Ryan Haight Online Pharmacy Act) required an in-person medical evaluation before prescribing controlled substances via telemedicine. During COVID, that requirement was waived, allowing providers to prescribe medications like Adderall or phentermine to new patients remotely.

Where We Stand Now

In January 2026, the DEA and HHS extended these telehealth flexibilities through December 31, 2026. This means you can continue prescribing controlled substances (including Schedule IV appetite suppressants like phentermine) via telehealth without an initial in-person visit—but only temporarily.

The DEA is developing permanent rules that will likely require either:

• A special telemedicine registration for certain prescribers
• Initial quantity limits (e.g., 30-day supply)
• State-specific restrictions (prescriber and patient in same state)

What This Means for Weight-Loss Medications

Here’s the critical distinction:

GLP-1 agonists (semaglutide/Wegovy, tirzepatide/Zepbound) are not controlled substances. You can prescribe these via telehealth in any state where you’re licensed, following standard prescribing guidelines. No DEA restriction applies.

Phentermine (Adipex-P) is a Schedule IV controlled substance. Under the current federal extension, you can prescribe it via telehealth to new patients nationwide—but you must:

• Have a valid DEA registration
• Check the state Prescription Drug Monitoring Program (PDMP)
• Follow state-specific telehealth requirements
• Document a proper evaluation (not just an online questionnaire)

The catch? Some states have imposed stricter rules than federal law, as we’ll see below.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Psychiatrist vs PMHNP: Scope of Practice for Weight Loss

Psychiatrists (MD/DO): Full Authority, Full Responsibility

As a physician, you can legally prescribe any FDA-approved medication, including weight-loss drugs. No state restricts physicians by specialty certification—a psychiatrist can manage hypertension, prescribe diabetes medications, or treat obesity.

But legal authority doesn’t equal clinical competence. If you prescribe weight-loss medications, medical boards will hold you to the same standard as any obesity medicine specialist. That means:

• Documenting appropriate indications (BMI ≥30 or ≥27 with comorbidities)
• Obtaining informed consent about risks and benefits
• Scheduling appropriate follow-up (typically monthly early in treatment, then quarterly)
• Coordinating with the patient’s primary care provider
• Understanding contraindications and drug interactions

Many psychiatrists pursue additional certification from the American Board of Obesity Medicine to strengthen their credibility and clinical foundation.

PMHNPs: Scope Uncertainty and Collaboration

Here’s where it gets tricky. Psychiatric Mental Health Nurse Practitioners are trained and certified to treat psychiatric disorders. Prescribing purely for obesity—a metabolic condition—may fall outside your scope of practice in many states.

State nursing boards expect NPs to practice within their training and certification. A PMHNP treating weight loss without physician collaboration or additional training could face scope-of-practice questions.

State-Specific NP Rules:

California: NPs need physician supervision via Standardized Procedures unless they meet AB 890 criteria for independent practice (phased in through 2026). Even with independence, a psych-certified NP prescribing for obesity (not mental health) might need additional protocols or physician consultation.

Texas: NPs require a Prescriptive Authority Agreement with a physician. For weight management, that supervising physician should ideally have expertise in obesity or primary care—not just psychiatry.

Florida: APRNs need physician supervision unless they’ve attained autonomous practice status (currently limited to certain Family NPs). Psychiatric NPs still require collaboration.

New York: NPs can practice independently after 3,600 hours of supervised practice, but treating obesity may be considered outside a psychiatric NP’s usual scope without additional training.

The Practical Solution

If you’re a PMHNP interested in weight management:

1. Consider additional certification or training in obesity medicine
2. Establish a formal collaborative relationship with a physician experienced in weight management
3. Document protocols specifically addressing weight-loss treatment
4. Focus on patients where psychiatric and metabolic issues overlap (e.g., antipsychotic-induced weight gain, binge eating disorder)

State-by-State Breakdown: Where Can You Prescribe?

California: Strict Corporate Practice Rules, Liberal Telehealth

Telehealth Prescribing: California allows telehealth exams to meet the ‘appropriate prior examination’ requirement. No in-person visit needed for GLP-1s or phentermine if you conduct a proper video evaluation.

Key Requirements:

• Telehealth consent: Mandatory under B&P §2290.5—document patient consent
• PDMP checks: Query CURES before prescribing any Schedule II-IV drug (including phentermine) and every 4 months thereafter
• E-prescribing: All prescriptions must be electronic
• Corporate Practice of Medicine: Only physician-owned entities can provide medical services—non-physicians can’t independently run weight-loss clinics

PMHNP Considerations: NPs need Standardized Procedures with physician oversight unless they qualify for independent practice under AB 890 (available to experienced NPs starting 2026, but limited to their certified specialty—mental health for PMHNPs).

Local Reality: Medi-Cal will stop covering GLP-1 medications for weight loss in January 2026, pushing patients toward cash-pay models. High demand in urban areas, but strict advertising rules (B&P §651) prohibit misleading claims.

Texas: NP Delegation Required, Telehealth Friendly

Telehealth Prescribing: Texas allows telehealth prescribing via live video with no in-person requirement for weight-loss medications (both controlled and non-controlled).

Key Requirements:

• Valid telehealth relationship: Must use synchronous audio-video or store-and-forward with audio
• Follow-up mandate: Send report to patient’s PCP within 72 hours (with consent)
• PDMP: Check Texas PMP for controlled substances (phentermine recommended though not explicitly mandated)
• NP/PA delegation: Prescriptive Authority Agreement required; supervising physician should have relevant expertise

PMHNP Considerations: Must practice under physician delegation. For weight management, the delegating physician should ideally be in primary care or obesity medicine, not just psychiatry.

Local Reality: Texas has high obesity rates and strong telehealth adoption. But the state has cracked down on weight-loss clinics for misleading advertising—ensure compliance with professional standards and transparent pricing.

Florida: Explicit Obesity Rules, Psych Exception for Schedule IIs

Telehealth Prescribing: Florida explicitly allows telehealth for obesity treatment but prohibits teleprescribing Schedule II controlled substances except for psychiatric treatment.

Key Requirements (Florida Administrative Code 64B8-9.012):

• BMI documentation: Patient must have BMI ≥30 (or ≥27 with comorbidities)
• Written informed consent: Mandatory for all weight-loss medications
• Quarterly re-evaluations: At least every 3 months for patients on anti-obesity medications
• Consumer Bill of Rights: Must provide to each patient
• PDMP checks: Required before prescribing any controlled substance (E-FORCSE database)

Psychiatrist Advantage: Florida’s telehealth law allows psychiatrists to prescribe Schedule II controlled substances (like Adderall) via telehealth for psychiatric disorders—but not for weight loss. Phentermine (Schedule IV) is permitted via telehealth for obesity.

PMHNP Considerations: Requires physician supervision unless you’ve achieved autonomous practice status (limited to certain Family NPs, not psychiatric NPs as of 2025).

Local Reality: Florida’s Commercial Weight-Loss Practices Act requires written price quotes and prohibits guarantees of specific results. Strong demand but heavy regulatory oversight—document everything.

New York: Strictest Controlled Substance Rules

Telehealth Prescribing: New York requires an in-person evaluation before prescribing any controlled substance (10 NYCRR §80.63), with narrow exceptions.

The In-Person Rule:You cannot prescribe phentermine via telehealth to a new patient unless:

• Another NY provider examined the patient in-person within the past 12 months and shared records
• You’re covering for a colleague who saw the patient in-person
• It’s an emergency for an existing patient (5-day supply maximum)

For GLP-1 Medications: No restrictions—these aren’t controlled, so standard telehealth prescribing applies.

Key Requirements:

• PDMP checks: Mandatory within 24 hours before prescribing any Schedule II-IV drug
• E-prescribing: All prescriptions must be electronic (EPCS required for controlled substances)

PMHNP Considerations: After 3,600 hours of practice, NPs can work independently, but treating obesity may be outside psychiatric scope. Consider physician collaboration for weight management.

Local Reality: The strict in-person rule forces many telehealth providers to partner with local clinics for initial visits when controlled substances are involved. For pure GLP-1 services, you’re clear to operate via telehealth alone.

Pennsylvania: No Specific Telehealth Law, Standard Practice Applies

Telehealth Prescribing: Pennsylvania defers to federal law—currently allows controlled substance prescribing via telehealth under the DEA extension.

Key Requirements:

• PDMP checks: Required before first opioid/benzodiazepine prescription, then each time for those drug classes. Recommended for all controlled substances including phentermine
• Standard of care: Must document evaluation equivalent to in-person visit

PMHNP Considerations: Collaborative Agreement required for prescribing. No independent practice for NPs in Pennsylvania (legislation pending but not passed).

Local Reality: Mix of urban (Philadelphia/Pittsburgh) and rural areas. Telehealth fills access gaps in rural PA, but patients often have strong ties to local healthcare systems—coordinate with PCPs for best outcomes.

Illinois: Most Telehealth-Friendly, NP Independence Available

Telehealth Prescribing: Illinois explicitly allows telehealth to establish patient relationships and prescribe medications, including controlled substances.

Key Requirements:

• No in-person mandate: Telehealth exam sufficient if it meets standard of care
• E-prescribing: All controlled substances must be e-prescribed (effective Jan 2023)
• PDMP checks: Mandatory for Schedule II narcotics; recommended for all controlled substances

PMHNP Considerations: Illinois offers Full Practice Authority for APRNs who complete 4,000 hours of clinical experience and additional training. With FPA, psychiatric NPs can prescribe independently—but treating obesity may still be questioned as outside mental health scope.

Local Reality: Chicago and suburbs have high competition from hospital-based weight management programs. Telehealth works well for reaching rural Illinois. Medicaid covers some weight-loss medications (Wegovy) as of 2024, increasing demand.

The Economics: What Does Patient Acquisition Actually Cost?

Let’s address the elephant in the room: many providers assume they can acquire patients cheaply through DIY marketing. The reality is far different.

The Real Cost of DIY Patient Acquisition

When you factor in all costs of acquiring a qualified psychiatric or weight-loss patient through self-marketing:

SEO: Takes 6-12 months of consistent investment ($2,000-5,000/month for agencies) before generating meaningful patient flow. Most solo providers don’t have this expertise or patience.

Google Ads: Mental health and weight-loss keywords cost $15-40+ per click. With typical conversion rates, a booked patient costs $200-400+ after accounting for:

• Ad spend
• Failed campaigns and testing
• Staff time to qualify leads
• No-show rates from cold leads

Directory Listings: Psychology Today charges monthly fees and you compete with hundreds of providers. Zocdoc charges $35-100+ per booking plus monthly subscription. Total monthly cost adds up fast.

True CAC Reality: When you honestly account for agency fees, ad spend, staff time, no-shows, and months of investment before results, acquiring a qualified patient through DIY marketing typically costs $200-500+—not the $30-50 some marketing materials claim.

The Platform Alternative: Guaranteed ROI

This is where Klarity Health’s model makes economic sense. Instead of spending $3,000-5,000/month on marketing with uncertain results, you pay a standard listing fee only when a qualified patient books with you.

Value propositions:

• No upfront marketing spend or monthly subscriptions
• Pre-qualified patients already matched to your specialty and availability
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule—only pay when you see patients

Instead of gambling on marketing channels, you get guaranteed ROI: every dollar spent equals a qualified patient appointment.

Compliance Best Practices: Avoiding Regulatory Pitfalls

Medical boards and the DEA are watching telehealth weight-loss prescribing closely. Primary care physicians express concern about ‘clinically inappropriate’ prescribing by online services and poor continuity of care.

Essential Safeguards:

1. Document Thoroughly

• Full history including psychiatric medications (for drug interactions)
• Weight history and previous weight-loss attempts
• Contraindications (pregnancy, cardiovascular disease, eating disorders)
• BMI calculation and comorbidities
• Informed consent discussion
• Follow-up plan

2. State-Specific Compliance

• Florida: Provide Consumer Bill of Rights, schedule quarterly follow-ups, document BMI
• New York: For controlled substances, ensure in-person exam occurred (or use GLP-1s only)
• California: Obtain documented telehealth consent, check CURES every 4 months
• Texas: Send PCP report within 72 hours (with patient consent)

3. Clinical CoordinationMany states (New Jersey, Virginia) require psychiatric evaluation and diet/exercise counseling before prescribing weight-loss medications. Even where not mandated, this is standard of care.

Consider:

• Referring to nutrition specialists
• Coordinating with the patient’s PCP
• Screening for eating disorders and depression
• Monitoring for side effects (GLP-1 GI effects, phentermine cardiovascular effects)

4. Advertising ComplianceState medical boards and consumer protection laws prohibit:

• Guaranteeing specific weight-loss results
• Misleading claims about FDA approval (especially for compounded medications)
• Implying medical credentials for non-physicians
• Promising ‘easy’ or ‘effortless’ weight loss

FAQ: Common Questions About Weight-Loss Prescribing

Can I prescribe GLP-1 weight-loss medications via telehealth to new patients?

Yes, in all states where you’re licensed. GLP-1 medications (semaglutide, tirzepatide) aren’t controlled substances, so they’re not subject to DEA’s in-person exam requirement. You must conduct a proper telehealth evaluation meeting your state’s standard of care and document appropriate indications.

Do I need an in-person visit to prescribe phentermine online?

It depends on your state. Under current federal rules (through December 2026), no in-person visit is required. However:

• New York: Yes, requires in-person exam (with narrow exceptions)
• Texas, Florida, California, Pennsylvania, Illinois: No, telehealth-only is permitted under current law

Always verify your specific state’s requirements, as this may change when permanent DEA rules take effect.

As a PMHNP, can I offer weight-loss treatment?

Legally questionable in most states without physician collaboration or additional certification. Your scope of practice is mental health treatment—prescribing solely for obesity may be viewed as outside your training unless:

• You practice under physician protocols (in states requiring collaboration)
• You obtain additional training/certification in obesity medicine
• You focus on patients where psychiatric and metabolic issues overlap (e.g., antipsychotic-induced weight gain)

State nursing boards scrutinize NPs practicing outside their certified specialty. Document your rationale and ensure proper oversight.

What are the risks of compounded semaglutide from telehealth clinics?

Over half of primary care physicians in a 2025 survey expressed concern about patient safety with telehealth GLP-1 prescribers, citing worries about compounded medications lacking FDA oversight, inadequate monitoring, and poor continuity of care. If prescribing compounded GLP-1s:

• Verify pharmacy compliance with USP standards
• Counsel patients that compounded versions aren’t FDA-approved
• Monitor more closely for adverse effects
• Document why compounded vs. brand-name medication

How often must I see weight-loss patients for follow-up?

Varies by state:

• Florida: At least every 3 months (state law requirement)
• Virginia: Within 30 days of starting therapy, then ongoing
• National guidelines: Monthly early in treatment (for dose titration and side effect monitoring), then every 3 months once stable

Frequent follow-up isn’t just good medicine—it’s what medical boards expect when reviewing telehealth cases.

Can psychiatrists treat obesity alongside mental health conditions?

Absolutely. Many psychiatric patients struggle with weight—either from psychiatric medications or comorbid conditions like binge eating disorder. Psychiatrists are uniquely positioned to address both the mental health and metabolic aspects of care. Just ensure:

• You’re comfortable managing the medical aspects (or collaborating with a provider who is)
• You document competence (additional training, certification, or consultation)
• You follow state obesity treatment guidelines where they exist

The Bottom Line: Opportunity Meets Responsibility

Weight-loss prescribing via telehealth represents a real opportunity for psychiatric providers—especially as GLP-1 medications gain mainstream acceptance and patient demand grows. For psychiatrists, it’s an extension of comprehensive patient care (managing medication-induced weight gain, treating eating disorders alongside metabolic health). For some experienced PMHNPs, it could be an additional service with proper physician collaboration.

But this opportunity comes with genuine regulatory and clinical responsibility. The landscape is complex:

• Federal DEA rules are in flux (current extension through 2026, permanent rules pending)
• State requirements vary dramatically (New York’s strict in-person rule vs. Illinois’ permissive approach)
• Scope-of-practice questions loom for PMHNPs
• Medical boards are scrutinizing telehealth weight-loss services for quality and safety

The Smart Approach:

1. Know your state’s specific rules before prescribing weight-loss medications via telehealth
2. Document thoroughly—medical board reviews focus on whether your evaluation was adequate
3. Coordinate care with patients’ primary providers, especially for metabolic monitoring
4. Consider platforms that handle patient acquisition and compliance infrastructure, removing the risk and cost of DIY marketing
5. Stay current on evolving regulations (subscribe to DEA updates, state medical board newsletters)

The economic case is clear: instead of spending thousands monthly on uncertain marketing results, platforms like Klarity Health let you pay only when qualified patients book appointments. That’s guaranteed ROI vs. gambling on SEO or Google Ads that may take months to generate leads.

For psychiatric providers ready to expand into weight management—or simply help your existing patients more comprehensively—the telehealth opportunity is real. Just make sure you’re building on a foundation of solid compliance, clinical competence, and patient safety.

Ready to see qualified weight-loss patients without the marketing headaches? [Explore how Klarity Health connects providers with pre-screened patients ready for treatment—no upfront costs, no wasted ad spend, just appointments when you want them.]

Sources and References

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.cchpca.org/topic/online-prescribing/#:~:text=No%20controlled%20substance%20shall%20be,for%20the%20medical%20evaluation%2C%20and
• https://florida.public.law/statutes/fla.stat.456.47#:~:text=provider%20is%20not%20required%20to,is%20prescribed%20for%20the%20following
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=Florida%20law%20restricts%20the%20prescribing,5
• https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/#:~:text=2000%20%28Fla,loss%20providers%20are%20required%20to
• https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/#:~:text=medical%20director%20and%20retain%20full,Clinics%20must%20maintain%20DEA
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,require%20DEA%20registration
• https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey#:~:text=Primary%20care%20physicians%20are%20mainly,cited%20by%20half%20of%20physicians
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated